To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

20.702 days ago
21.00a day ago
arrow

LOWER/UPPER CIRCUITS

20.70
21.54
arrow
Beryl Drugs Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
notePrice to Earning Ratio,is 18.18, lower than its sector PE ratio of 43.7.
noteQuarterly Revenue,rose 33.54% YoY to ₹5.22 Cr. Its sector's average revenue growth YoY for the quarter was 11.41%.
noteQuarterly Net profit,rose 143.75% YoY to ₹0.15 Cr. Its sector's average net profit growth YoY for the quarter was 37.72%.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 28.53%
Net profit growth 5Y CAGR : 5.38%
Beryl Drugs Limited is incorporated on August 24, 1993 under the provisions of The Companies Act, 1956. The company is engaged in the sole segment of pharmaceuticals manufacturing. The company has come a long way and emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products.
personal

Grow your wealth with more research recommendations

+91